Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia
Biotech
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
GlycoMimetics CEO Harout Semerjian said in March that phase 3 blood cancer data could “fundamentally impact our company's trajectory.” He was right.
Nick Paul Taylor
May 6, 2024 8:11am
Nkarta's blood cancer CAR stalls again, driving deprioritization
Mar 22, 2024 9:11am
BMS snags another ADC with modest $100M Orum deal
Nov 6, 2023 7:00am
Incyte drops Syros blood cancer partnership, following Pfizer
Aug 14, 2023 10:45am
Death drives Magenta to pause antibody-drug conjugate trial
Jan 26, 2023 6:20am
Jasper pulls out of pivotal blood cancer trial at last minute
Jan 10, 2023 10:20am